Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    22674807 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting UARK 2003-33, Total Therapy III
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide
2 Active, not recruiting UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (Velcade);   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Lenalidomide
3 Terminated
Has Results
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
Condition: Multiple Myeloma
Interventions: Drug: Velcade, Thalidomide, and Dexamethasone;   Drug: Velcade, Melphalan, and Dexamethasone

Indicates status has not been verified in more than two years